Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ROZEX GEL 0.75% [SIN08453P]

Active ingredients: ROZEX GEL 0.75%

View product's general information
Last updated 24 April 2026

Product Info

ROZEX GEL 0.75%

[SIN08453P]

Product information

Active Ingredient and Strength

METRONIDAZOLE - 0.75%

Dosage Form

GEL

Manufacturer and Country

LABORATOIRES GALDERMA - FRANCE

Registration Number

SIN08453P

Licence Holder

GALDERMA SINGAPORE PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

D06BX01

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS AND USAGE
ROZEX Gel is indicated for topical application in the treatment of inflammatory papules, pustules and erythema of rosacea.

Dosing

DOSAGE AND ADMINISTRATION
Apply and rub in a thin film of ROZEX twice daily, morning and evening, to the entire affected areas after washing. Significant therapeutic results should be noticed within three weeks. Clinical studies have demonstrated continuing improvement through nine weeks of therapy. Areas to be treated should be cleansed before application of ROZEX. Patients may use cosmetics after application of ROZEX.

Contraindications

CONTRA-INDICATIONS
Rozex Gel is contraindicated in individuals with a history of hypersensitivity to metronidazole, parabens, or other Ingredients of the formulation.
Metronidazole must not be used in patients with Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use.